Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Camurus (NASDAQ STO: CAMX) and Eli Lilly and Company ("Lilly") have entered a collaboration and license agreement, granting Lilly exclusive, worldwide rights to the research, development, manufacture, ...

Camurus maintained its full-year 2025 guidance, projecting revenue between SEK 2.7-3.0 billion (45-61% growth versus 2024) and profit before tax of SEK 0.9-1.2 billion (63-117% growth versus 2024).

Camurus eligible to receive up to $870 million in potential development and sales milestone payments and mid-single-digit royalty "We are pleased to enter into this collaboration with Lilly to ...

Introduction & Market Context Camurus AB (STO:CAMX) presented its first quarter 2025 results on May 15, revealing strong financial performance despite challenging market conditions. The Swedish ...